The Daily Dose: Novartis denies a sick toddler compassionate use and more salty Pharma stories

Words matter. Images matter. The Scientific Inquirer needs your support. Help us pay our contributors for their hard work. Visit our Patreon page and discover ways that you can make a difference. http://bit.ly/2jjiagi

A significant portion of the public have negative perceptions of pharmaceutical companies, particularly when it comes to pricing. So nobody needs to tell you that the pharma-giant denying a very sick toddler compassionate use of its not-yet-approved gene therapy drug, Zolgensma, is not a good look. In fact, the optics are outright ugly and the company looks more than a little salty. It happened. “The Brussels Times reported that De Block’s spokesperson Audrey Dorigo said Novartis had rejected a request for compassionate use, even though the government considered that all conditions were met.” Did I mention how ugly this situation looks? http://bit.ly/2lxQn0n

While we’re on the topic of Zolgensma, it’s hard not to mention the fact that the drug’s story is almost as negative as it can be while still being positive. A baby died during a clinical trial in Europe. Meanwhile, Novartis was called out for submitting questionable data. Not only that, a JPMorgan survey of physicians made clear that there were some reservations about the drug’s effectiveness. There are whispers that the drug will struggle to be profitable. http://bit.ly/2lvJ758

Chalk another one up for cannabis pharma front-runner, GW Pharma has had it’s epilepsy drug approved in the European Union. That’s good news. (See, it’s not all pharma bashing here today.) http://bit.ly/2mXrGe0

So back to the unflattering Big Pharma narratives. (Really, they do it to themselves quite a bit.) According to FiercePharma, “As U.S. officials press a massive case for alleged generic drug price fixing, authorities in the U.K. have unearthed an example of rivals working a little too closely with each other.” Click on. Read on. Get mad. http://bit.ly/2n2NCof

IMAGE SOURCE: Creative Commons

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: